Stable transformation of *Babesia bigemina* and *Babesia bovis* using a single transfection plasmid

Marta G. Silva¹, Donald P. Knowles¹,², Monica L. Mazuz³, Brian M. Cooke⁴ & Carlos E. Suarez¹,²

*Babesia bigemina* and *Babesia bovis*, are the two major causes of bovine babesiosis, a global neglected disease in need of improved methods of control. Here, we describe a shared method for the stable transfection of these two parasites using electroporation and blasticidin/blasticidin deaminase as a selectable marker. Stably transfected *B. bigemina* and *B. bovis* were obtained using a common transfection plasmid targeting the enhanced green fluorescent protein-BSD (egfp-bsd) fusion gene into the elongation factor-1α (ef-1α) locus of *B. bigemina* and *B. bovis* under the control of the *B. bigemina* ef-1α promoter. Sequencing, Southern blotting, immunoblotting and immunofluorescence analysis of parasite-infected red blood cells, demonstrated that the egfp-bsd gene was expressed and stably integrated solely into the ef-1α locus of both, *B. bigemina* and *B. bovis*. Interestingly, heterologous *B. bigemina* ef-1α sequences were able to drive integration into the *B. bovis* genome by homologous recombination, and the stably integrated *B. bigemina* ef-1α-A promoter is fully functional in *B. bovis*. Collectively, the data provides a new tool for genetic analysis of these parasites, and suggests that the development of vaccine platform delivery systems based on transfected *B. bovis* and *B. bigemina* parasites using homologous and heterologous promoters is feasible.

Bovine babesiosis caused by *Babesia bovis* and *B. bigemina* is an acute and persistent tick-borne disease with a high negative economic impact worldwide. The disease is characterized by high mortality and morbidity in susceptible animals that develop fever, anemia, jaundice, weight lost, reduction in milk production and, in severe cases, death. Animals that survive an acute infection become long-term asymptomatic carriers of the parasites. Persistently infected animals are therefore a continuous source for transmission by ticks and the maintenance of herd immunity⁵.

*B. bigemina* is usually regarded as having relatively reduced virulence compared to *B. bovis* however, *B. bigemina* is also responsible for important economic losses worldwide and improved methods of control are urgently needed. Currently control of babesiosis is achieved by acaricides and live-attenuated vaccines, but these approaches have serious limitations, including the development of acaricide resistance by ticks, and current efforts are focused on the development of novel and more effective recombinant protein sub-unit vaccines or genetically-attenuated parasites. The development of stable transfection systems for *B. bovis*⁶,⁷, have already facilitated several new avenues of research, including functional gene characterization⁵ and novel vaccine development⁶,⁸, but such methods are not available for *B. bigemina*. The development of genetic manipulation tools for *B. bigemina* will advance our understanding of parasite biology, gene function and improved control of bovine babesiosis⁶,⁷. A recent study described an effective *B. bigemina* promoter, interspecies (*B. bovis* and *B. bigemina*) activity for the elongation factor (ef)−1α promoters, and a method for incorporating exogenous DNA into *B. bigemina*, but appropriate selectable markers and a permissible site for stable integration of transfected genes remained undefined. However, initial *B. bovis* transfection systems were based on the use of the blasticidin and blasticidin deaminase (BSD) as a selectable marker, and the ef-1α locus as a permissible site for targeting exogenous gene integration⁴. Importantly, the availability of a partial *B. bigemina* genome (http://www.sanger.ac.uk/resources/downloads/protozoa/babesia-bigemina.html) and the previous characterization of the *B. bigemina* ef-1α locus⁹, indicate that the structure of this locus is essentially identical in both *B. bigemina* and *B. bovis*.

¹Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington, United States of America. ²Animal Disease Research Unit, Agricultural Research Service, USDA, WSU, Pullman, Washington, United States of America. ³Division of Parasitology, Kimron Veterinary Institute, P.O.B. 12, Bet Dagan, 50250, Israel. ⁴Department of Microbiology, Biomedicine Discovery Institute, Monash University, Victoria, 3800, Australia. Correspondence and requests for materials should be addressed to M.G.S. (email: marta_silva@wsu.edu)

10.1038/s41598-018-23010-4

Published online: 17 April 2018
Together, these observations suggest that it would be feasible to use a common strategy for gene integration in both *B. bovis* and *B. bigemina*, based on targeting one of the two identical *ef-1α* open reading frames (ORFs) present in the *ef-1α* locus.

Here, we describe for the first time a stable transfection system for *B. bigemina* based on integration of the egfp-bsd gene under the control of the *ef-1α* promoter, into the *ef-1α* locus of *B. bigemina*, after drug selection with blasticidin. In addition, the same plasmid used for transfection of *B. bigemina* was able to insert and express foreign sequences in the *ef-1α* locus of *B. bovis*, thus expanding the options available for the genetic manipulation of *Babesia* sp. parasites more generally.

**Materials and Methods**

**Ethics statement.** Animals (*Bos taurus* Holstein steers, 12–20 months old) were used as blood donors for the maintenance of *in vitro* cultures of *B. bigemina* and *B. bovis* and were approved by the Institutional Animal Care and Use Committee (protocol 2013–66). All experiments performed in this study were conducted in accordance with the Protocol of Animal Usage Number 2013–66 approved by the University of Idaho IACUC Committee.

**In vitro parasite culture.** *B. bigemina* (Puerto Rico strain) and *B. bovis* (T, Bo strain) were propagated in continuous microaerophilic stationary-phase culture as previously described. Briefly, *B. bigemina* and *B. bovis* cultures were grown in 96-well plates in bovine red blood cells (RBC) at 5% or 10% hematocrit, respectively, using HL-1 culture media at pH 7.2, and were incubated at 37 °C in an atmosphere of 5% CO₂ and 90% N₂.

**Evaluation of sensitivity of *B. bigemina* and *B. bovis* to blasticidin.** *B. bigemina* and *B. bovis* parasites were cultured in 180 μl of culture medium containing 5% and 10% bovine RBC, respectively, in a 96-well plate with different concentrations of blasticidin: 1, 1.2, 1.5, 1.8, 2, 4, 6, 8, 10, 12 and 14 μg/μl. Media without blasticidin was used as a control. The initial parasitemia was 0.2%. One hundred and fifty μl of culture media was daily replaced with corresponding amount of blasticidin. Percentage of parasitized erythrocytes (PPE) was monitored daily by Diff-Quik stained smears every 24 hr over a period of 72 hr by light microscopy (1000 × magnification). This experiment was carried out in triplicate.

**Parasite DNA extraction.** Genomic DNA (gDNA) and plasmid DNA (pDNA) was extracted from cultured *B. bigemina* and *B. bovis* using the Qiagen Blood core kit according to the manufacturer’s instructions.

**Plasmid constructs.** The 3’ and 5’ insertion target regions for stable transfection in the *ef-1α*-alpha-*B* ORF were generated by PCR with *B. bigemina* gDNA isolated from tissue culture cells utilizing the following sets of primers: Bbig-EF-orf-B-3’-BamHI-F and Bbig-EF-orf-B-3’-BamHI-R primers for the 3’ region of *B. bigemina* EF (expected size of 678 base pair (bp) amplicon); Bbig-EF-orf-B-5’-Xho-F and Bbig-EF-orf-B-5’-Xho-R for the 5’ region of *B. bigemina* EF (expected size of 674 bp amplicon). These PCR products were cloned into the TOPO-TA 2.1 (Life technologies) cloning vector for sequence confirmation. The 3’ and 5’ insertion regions were then digested from the cloning vectors respectively with BamHI and Xhol restriction enzyme and the amplicons were isolated and recovered from a 1% agarose gel. The plasmid containing the *ef-1α*-A promoter and luciferase gene along with the 3’ rap-1a stop region used in the *B. bigemina* transient transfection was digested with EcoRI restriction enzyme to remove the luciferase gene and the resulting linearized vector now containing just the *B. bigemina* ef-1a-A promoter and *B. bigemina* 3’ rap-1a stop region was re-circularized by ligation and transformed into *E. coli* competent cells (Life Technologies). The purified vector was then digested with BamHI restriction enzyme and the 674 bp amplicon corresponding to 3’ ef-1α-B ORF insertion region was ligated into this linear vector, transformed into TOP-10 cells and sequenced to confirm the correction orientation of the insertion. The resulting vector was digested with Xhol restriction enzyme and a similar procedure was used to ligate the 5’ ef-1α-B ORF insertion target region into the vector. After confirming that both the 3’ and 5’ insertion sites were present in the correct orientation by sequencing, the vector was prepared for further ligation by digestion with EcoRI restriction enzyme. A synthetic egfp-bsd fusion gene from the p6-Cys-EKO plasmid (GenBank Accession number KX247384) containing EcoRI restriction sites was digested with EcoRI to remove the egfp-bsd fragment. This egfp-bsd fragment was isolated on a gel and the recovered fragment ligated into the vector containing the 3’ and 5’ *B. bigemina* insertion regions and the rap-1a 3’ stop region to generate the final stable transfection vector designated pbig-ef-egfp-bsd. The plasmid pbig-ef-egfp-bsd was used to transform TOP-10 cells, and plasmid was purified with the Qiagen Endotoxin free Plasmid Maxi Kit following the manufacturer’s instructions prior to transfection. The pBluescript (pBS) plasmid was used as a negative control in the transfection experiments.

**Transfection of *B. bigemina*.** The transfection of *B. bigemina*-infected RBC was performed as described by Suarez et al. Briefly, *B. bigemina* iRBC with PPE ~20% was centrifuged at 600 x g for 5 min, and the cells washed once with 1 ml of Cytomix buffer (120 mM KCl, 0.15 mM CaCl₂, 10 mM KH₂PO₄/K₂HPO₄, pH 7.6). Twenty μg of pbig-ef-egfp-bsd plasmid in 55 μl of cytomix was then gently mixed with 40 μl of washed *B. bigemina* iRBC then transferred to 0.2 cm electroporation cuvette and transected by electroporation using a BioRad Gene Pulser II system at 1.2 kV + 25 μF + 200 Ω. After transfection, cells were immediately transferred to a 24-well plate containing 1.2 ml of HL-1 media with 5% of bovine RBC and 8 μg/μl of bsd to select for egfp-bsd expressing transgenic parasites.

**Transfection of *B. bovis*.** The process for transfection of *B. bovis* parasites using plasmid pbig-ef-egfp-bsd was performed as described above for *B. bigemina*. After transfection, cells were immediately transferred to a 24-well plate containing 1.2 ml of HL-1 media with 10% of bovine RBC and 3 μg/μl of bsd to select for egfp-bsd expressing transgenic parasites.
wild-type parasites were cultured in 180 \mu l of culture medium containing 5% bovine RBC, in the absence of blasticidin and in the presence of 8 \mu g/\mu l of blasticidin. B. bovis (bovis-big-eGFP-bsd) and B. bovis wild-type parasites were cultured in 180 \mu l of culture medium containing 10% bovine RBC in the presence of 3 \mu g/\mu l of blasticidin or in the absence of blasticidin (positive control). The initial parasitemia was 0.2% and parasites were cultured in triplicate in 96-well plates. Medium (150 \mu l) was replaced daily. PPE was monitored every 24 hr up to 72 hr by Diff-Quik-stained RBC smears by optical microscope under 1000 \times amplification. This experiment was carried out in triplicate.

Southern blot analysis. Genomic DNA was extracted from wild-type B. bigemina and B. bovis parasites, bigemina-big-eGFP-bsd and bovis-big-eGFP-bsd with linearized pBS plasmid. One and half \mu g of gDNA were digested overnight with 10 units/\mu l of BglII restriction enzyme and electrophoresis was carried out on a 1% agarose gel containing SYBR green dye. Three DIG-labeled were used:

- gDNA were digested overnight with 10 units/\mu l of BglII restriction enzyme
- a control plasmid without labeled DNA marker II was used as standard molecular marker,
- pBS Babesia

Quantifying in vitro growth of B. bigemina and B. bovis. B. bigemina (bigemina-big-eGFP-bsd) and B. bigemina wild-type parasites were cultured in 180 \mu l of culture medium containing 5% bovine RBC, in the absence of blasticidin and in the presence of 8 \mu g/\mu l of blasticidin. B. bovis (bovis-big-eGFP-bsd) and B. bovis wild-type parasites were cultured in 180 \mu l of culture medium containing 10% bovine RBC in the presence of 3 \mu g/\mu l of blasticidin or in the absence of blasticidin (positive control). The initial parasitemia was 0.2% and parasites were cultured in triplicate in 96-well plates. Medium (150 \mu l) was replaced daily. PPE was monitored every 24 hr up to 72 hr by Diff-Quik-stained RBC smears by optical microscope under 1000 \times amplification. This experiment was carried out in triplicate.

PCR amplification and sequencing. Sets of primers were designed to confirm the integration of plasmid bigemina-big-eGFP-bsd and bovis-big-eGFP-bsd by specific amplification of a DNA fragments surrounding the 5′ recombination site, the 3′ recombination site and the locus (Table 1). Amplicons were cloned into pCR™2.1-TOPO vector (Life Technologies) according to the manufacturer’s instructions and nucleotide sequences were confirmed by Sanger sequencing (ABI 3730).

Immunoblot analysis. Proteins were extracted from cultured wild-type B. bigemina and B. bovis, bigemina-big-eGFP-bsd and bovis-big-eGFP-bsd and were used for immunoblot analysis as previously described. Briefly, the immunoblots were incubated with mouse monoclonal antibody (MAB) against B. bigemina rap-1 protein (64/4.10.3)14 diluted to 2 \mu g/ml. B. bovis and bovis-big-eGFP-bsd were incubated with mouse MAB against B. bovis rap-1 protein (23/53.156.77) diluted to 2 \mu g/ml; wild-type B. bigemina and B. bovis, bigemina-big-eGFP-bsd and bovis-big-eGFP-bsd were incubated with rabbit anti-GFP diluted to 1:5,000. Membranes were subsequently incubated with HRP-conjugated goat anti-mouse IgG diluted 1:10,000 (on 64/4.10.3 and 23/53.156.77 antibody) or with HRP-conjugated goat anti-rabbit IgG diluted 1:5,000 (on anti-GFP antibody) for 45 minutes at RT. Chemiluminescent detection employed ECL™ western blotting substrate followed by exposure to X-film. Pre-immune mouse serum or non-infected bovine RBC were used as controls.

Statistical analysis. Statistical significance was determined using ANOVA (GraphPad Prism 7 software). P < 0.05 were considered statistically significant.

Results

Growth inhibitory concentrations of blasticidin in B. bigemina and B. bovis. First we compared the inhibitory concentrations of blasticidin on in vitro cultured B. bigemina and B. bovis. Parasites were cultured in the presence of different concentrations of blasticidin ranging from 1 \mu g/\mu l to 14 \mu g/\mu l, and the PPE was calculated daily up to 72 hr (Suppl. Figure 1a and b). The results show that increasing blasticidin concentrations above 4 \mu g/\mu l correlated with decreasing PPE for B. bigemina. The calculated IC50 found for B. bigemina and B. bovis was 3 \mu g/\mu l and 0.8 \mu g/\mu l, respectively. However 8 \mu g/\mu l and 3 \mu g/\mu l of blasticidin completely inhibited the growth of B. bigemina and B. bovis respectively (Suppl. Figure 1a and b), demonstrating that blasticidin as an appropriate selective inhibitory drug for developing a stable transfection system for B. bigemina.
Generation of *B. bigemina* and *B. bovis* transfected lines stably expressing eGFPbsd under the control of a *B. bigemina* ef-1α promoter. *B. bigemina* and *B. bovis* parasites were electroporated with plasmid *pbig-ef-egfp-bsd* (Fig. 1a–c) followed by culturing in the presence of inhibitory doses of blasticidin. The transfection plasmid *pbig-ef-egfp-bsd* was designed for targeting the integration of the *egfp-bsd* selectable marker gene into the *ef-1α* locus of *B. bigemina* (Fig. 1b). Blasticidin resistant and green fluorescent *B. bigemina* and *B. bovis* parasites emerged 15 and 18 days after electroporation respectively, but no parasites were detectable in culture wells containing either control mock transfected or non-transfected or wild-type *B. bovis* and *B. bigemina* parasites growing in the presence of inhibitory doses of blasticidin (data not shown). The blasticidin-resistant parasites were maintained on blasticidin containing cultures for 2 months before analyzed for phenotypic and genotypic characterization. Analysis by fluorescence microscopy revealed intracellular expression of eGFP protein in the blasticidin-resistant *B. bigemina* and *B. bovis* transfected parasites, which were termed *bigemina-big-ef-egfp-bsd* and *bovis-big-ef-egfp-bsd*, respectively (Fig. 2a). As expected, no eGFP fluorescence was observed in *B. bigemina* and *B. bovis* wild-type control parasites (Fig. 2b).

Phenotypic comparison between non-transfected and transfected *Babesia* parasites. The *in vitro* growth rate of *bigemina-big-ef-egfp-bsd* and *bovis-big-ef-egfp-bsd* parasite lines, and wild-type parasites were compared. Notably, *bigemina-big-ef-egfp-bsd* parasites grew three times faster than wild-type parasites (*P* < 0.05) while *bigemina-big-ef-egfp-bsd* parasites grew at similar rate regardless of the presence or absence of blasticidin (Fig. 3a). However, as expected, *B. bigemina* wild-type parasites did not grow in the presence of blasticidin (Fig. 3a).

The *bovis-big-ef-egfp-bsd* parasites showed a higher rate of growth (*P* < 0.05) in blasticidin-free culture media (Fig. 3b) when compared to growth of *bovis-big-ef-egfp-bsd* parasites in the presence of blasticidin or the growth of wild-type parasites. Growth rates for *big-ef-egfp-bsd* and wild-type parasites in the presence or absence of blasticidin were indistinguishable (Fig. 3b). *B. bovis* wild-type parasites did not grow in the presence of blasticidin (Fig. 3b).

Genotypic and proteomic characterization of stable *B. bigemina* and *B. bovis* transfected parasites. The genotypic characterization of transfected parasites was performed by Southern blot analysis, PCR and sequencing of PCR products. Genomic DNA from transfected *bigemina-big-gfp-bsd* and *bovis-big-gfp-bsd* cell lines, non-transfected *B. bovis* and *B. bigemina* parental strains, and plasmid *pbig-ef-egfp-bsd*, were analyzed in Southern blots using *B. bovis msa-1* (Fig. 4a), *B. bigemina rap-1* (Fig. 4b), eGFP (Fig. 4c) and *ef-1α* (Fig. 4d) specific dig-labeled probes. The presence of a single band hybridizing with eGFP-bsd probe, only in the transfected parasites is consistent with a single site integration of the exogenous transfected eGFP-bsd gene in both *bigemina-big-ef-egfp-bsd* and *bovis-big-ef-egfp-bsd* cell lines (green boxes, Fig. 4c). Probing the blots with an *ef-1α* specific probe that hybridizes with sequences that are not included in the transfection constructs reveal an increase in the size of the *ef-1α* locus in the transfected parasites as a result of the insertion of the transfected genes. The calculated size of the *BgIII* restriction size containing the *ef-1α* locus of wild type *B. bigemina* and *B. bovis* are 16.4 and 18.8 Kb, respectively. However, the size of the locus, as detected by the specific labeled probe, was increased to 18.6 and 21 Kb, respectively, in both transfected parasite lines which matches with the predicted size of the stably inserted DNA (2.2 kb). As expected, the *rap-1* and *msa-1* probes react with identical patterns in transfected and non-transfected gDNA. Taken together, these results are consistent with stable integration of a single eGFP-bsd gene copy in both parasite species.

We then designed a PCR aimed at demonstrating correct integration of the exogenous gene into the *B. bigemina ef-1α* locus using primers based on the transfected egfp gene and sequences adjacent to the *ef-1α* locus of *B. bigemina* and *B. bovis* that are not present in the transfection plasmids (Figs 5 and 6, respectively). Genomic DNA derived from stably transfected and non-transfected (wild-type) control *B. bigemina* parasites were amplified by PCR using the set primers: A) egfp-Fwd and ef1α-Rev; and B) egfp-Fwd and egfp-Rev (Fig. 5 and Table 1). The expected band of 2.2 kb was observed only upon amplification of the transfected parasite line *bigemina-big-ef-egfp-bsd* but not on the gDNA derived from the wild-type *B. bigemina* parasites (Fig. 5a).
The sequence of the 2.2 kb PCR amplicon was consistent with integration of the transfected egfp-bsd gene and its flanking regions into the Bef-1α gene of B. bigemina by homologous recombination (GenBank accession nr: MG234552). In addition, control PCR reactions using primers representing sequences present only in the transfection plasmid (Fig. 5b) (egfp-Fwd and egfp-Rev) only amplify a similar fragment in the transfected line bigemina-big-ef-egfp-bsd and transfection plasmid pbig-ef-egfp-bsd, but not on the gDNA derived from the wild-type B. bigemina parasites. PCR amplifications performed using similar sets of primers on transfected bovis-big-ef-egfp-bsd and wild-type B. bovis parasites are shown in Fig. 6. Integration PCR using the set of primers egfp-Fwd and Bbov-UpS-efB-Rev yielded a ~2.2 kb band (Fig. 6a and Table 1) in gDNA of bovis-big-ef-egfp-bsd but not in gDNA from wild-type B. bovis parasites. Sequencing of the 2.2 kb amplicon is consistent with integration of the transfected egfp-bsd gene and its flanking regions into the B. bovis genome by homologous recombination (GenBank accession nr: MG234553). Interestingly, sequencing of the PCR amplicon demonstrates the generation of a theoretically predictable hybrid partial B. bigemina-B. bovis ef-1α molecule in the transfected parasite. A comparison among the sequences of the hybrid portion of the molecule and the ef-1α DNA sequence of B. bovis and B. bigemina for the region involved in the insertion of the transfected genes into the genomes of the parasites is shown in Fig. 6b. Figure 6c also show alignments among the regions of insertion of the transfected genes into B. bovis and B. bigemina transfected parasites. PCR amplifications using primers rap-1a-Fwd and rap-1a-Rev confirmed the presence of the rap-1a gene in gDNA from transfected and wild-type parasites (Fig. 6b). An amplicon of ~320 bp was obtained (Fig. 6b).
We also performed immunoblotting to confirm expression of eGFP-BSD by the transfected *B. bigemina* and *B. bovis* parasites. As can be seen in the immunoblot, no reactivity was observed for any of the antibodies used and uninfected bovine RBC (Fig. 7a and lanes 5). The wild-type *B. bigemina* and *B. bovis*-big-ef-egfp-bsd reacted against *B. bigemina* rap-1 protein (~50 kDa) and the *B. bovis* and *B. bovis*-big-ef-egfp-bsd reacted against *B. bovis* rap-1 protein (~50 kDa) (Fig. 7b,c) using anti-RAP-1 MAbs as positive controls. Also, anti-GFP antibodies reacted with proteins present in both *B. bigemina*-big-ef-egfp-bsd and *B. bovis*-big-ef-egfp-bsd parasite lines with the expected molecular weight of the GFP-BSD fusion protein (~40 kDa), but not in wild-type *B. bigemina* and *B. bovis* (Fig. 7d).

Taken together, Southern blot, PCR and immunoblot data confirmed stable integration of the *egfp-bsd* gene into the genomes of both *B. bovis* and *B. bigemina* with demonstrated expression of the transfected exogenous genes.

**Discussion**

Here, a stable transfection of *B. bigemina* and *B. bovis* using identical *B. bigemina* insertion and gene regulatory sequences that can be used for functional gene characterization or for the delivery of exogenous antigens by *Babesia* spp. parasites is described. Importantly, the transfected *egfp-bsd* gene integrated as a single copy in the expected ef-1α locus in transfected *B. bigemina* parasites and no episomal forms of exogenous DNA *bigemina*-big-ef-egfp-bsd were detectable in parasites that were selected with blasticidin for at least two months.

A similar pattern of specific integration by means of homologous recombination for the exogenous transfection vector designed for integration into the *B. bigemina* ef-1α locus, despite the occurrence of sequence divergence in the ef-1α gene among the two species. Sequence comparisons among the ef-1α orf of *B. bovis* and *B. bigemina* show a level of identity of 87.45%. (Suppl. Figure 2 and Suppl. Table 1). Remarkably, that level of identity was sufficient to allow specific integration of the pbig-ef-egfp-bsd gene into the ef-1α locus of *B. bovis* genome, generating a hybrid ef-1α molecule in transfected *B. bovis*. The DNA sequence comparisons between ef-1α locus of *B. bigemina* and *B. bovis* (Suppl. Figure 2) provide hints on the mechanisms of homologous recombination operating in the parasite. Additionally, and consistent with previous findings, the ef-1α promoter of *B. bigemina* was able to generate expression levels of the egfp-bsd gene that are sufficient to sustain growth of transfected parasites at high levels of blasticidin. The strategy for exogenous gene insertion used in this study makes expression of the transfected egfp-bsd gene by the “native” *B. bigemina* promoter theoretically possible, but this possibility is highly unlikely since the homologous or heterologous ef-1α promoter region (~700 bp), located immediately downstream the truncated ef-1α orf contain numerous stop codons. In addition, we previously demonstrated heterologous promoter function using transient transfection, where the transfected gene is expressed under the control of the sequences present in the transfection plasmid, and without the intervention of the original promoters, supporting the contention that the exogenous integrated promoter is indeed responsible for the expression of the egfp-bsd gene in the stably transfected parasites. Transfected *B. bigemina* parasites grew three times faster than non-transfected (wild-type) parasites. This might be due to changes in the regulation of the expression of ef-1α locus in the transfected parasites. It will be interesting to determine whether these changes affect the ability and efficiency of the parasite to infect bovine and tick hosts, and whether they are associated with parasite virulence.
The ability to transfect *B. bigemina* and *B. bovis* using *B. bigemina* insertion and promoter sequences also has important implications for improving the design of Babesia sp.-based vectored vaccines. On one hand, a vaccine delivery platform based on *B. bigemina* transfected parasites might be more advantageous compared with *B. bovis* since the former parasite is known to cause less severe clinical disease in cattle, and, in contrast to *B. bovis*, does not result in microvascular sequestration of iRBC in the host. In contrast to *B. bovis*, *B. bigemina* parasites can be cleared from persistently infected animals, and dual *B. bovis*-*B. bigemina* infections are frequent in cattle in endemic areas.

Possible future applications of this transfection platform include the use of attenuated *B. bigemina*-transfected parasites that express *B. bovis* and/or vector tick antigens that induce parasite and/or vector controlling immunity during subclinical persistent infection. These vectored vaccines might become ideal to generate protective immunity effective against both bovine parasites and their vector.

In summary, we describe an efficient method for the stable transfection of *B. bigemina* that can be used for the future development of novel vaccines. These will require assuring that the transfected parasites are safe to deploy and that the genetic modifications do not result in undesirable phenotypic characteristics in potential vaccine candidate strains. The observation that the *B. bigemina*-specific construct can also be effectively and specifically used

---

**Figure 4.** Southern blot analysis using dig-labeled probes against: (a) *B. bigemina* rap-1α; (b) *B. bovis* msa-1; (c) egfp and (d) ef1α-α. 1: wild-type *B. bigemina* gDNA digested with BglII; 2: wild-type *B. bigemina* gDNA undigested; 3: *bigemina-big-ef-egfp-bsd* digested with BglII; 4: *bigemina-big-ef-egfp-bsd* undigested; DM: Dig labeled DNA marker II; Pr-: pBS promoterless control plasmid; C-: pbig-ef-egfp-bsd plasmid control; 5: wild-type *B. bovis* gDNA digested with BglII; 6: wild-type *B. bovis* gDNA undigested; 7: *bovis-big-ef-egfp-bsd* digested with BglII; 8: *bovis-big-ef-egfp-bsd* undigested. Vertical black stripes on the blot indicate cropping of the blot. A full image of the original blot can be seen in Supplementary Info section.

**Figure 5.** PCR integration analysis in *B. bigemina* using two different set of primers. (a) egfp-Fwd and ef1α-Rev. (b) egfp-Fwd and egfp-Rev. Line 1: wild-type *B. bigemina* gDNA; Line 2: *bigemina-big-ef-egfp-bsd*; C-: pbig-ef-egfp-bsd plasmid control; MW: molecular size ladder in bp, 1 Kb Plus DNA ladder.
to transfect *B. bovis* parasites expands the range of possibilities toward the development of novel vaccines. Future work is aimed at determining whether transfected *B. bigemina* parasites are able to express exogenous or homologous antigens as vaccine platforms, and work as an effective method for functional genetic analysis in *B. bigemina*.

The use of *B. bigemina* promoters in stably transfected *B. bovis* parasites also expands the toolbox available for the genetic manipulation of this parasite towards improved gene function characterization and vaccine development.
References
1. Mahoney, D. F., Wright, I. G. & Mirre, G. B. Bovine babesiosis: the persistence of immunity to *Babesia argentina* and *B. bigemina* in calves (*Bos taurus*) after naturally acquired infection. *Annals of tropical medicine and parasitology* **67**, 197–203 (1973).
2. Suarez, C. E. & McElwain, T. F. Stable expression of a GFP-BSD fusion protein in *Babesia bovis* meronts. *International journal for parasitology* **39**, 289–297, https://doi.org/10.1016/j.ijpara.2008.06.006 (2009).
3. Suarez, C. E. & McElwain, T. F. Transfection systems for *Babesia bovis*: a review of methods for the transient and stable expression of exogenous genes. *Veterinary parasitology* **167**, 205–215, https://doi.org/10.1016/j.vetpar.2009.09.022 (2010).
4. Asada, M. et al. Transfection of *Babesia bovis* by Double Selection with WR99210 and Blastocidin-S and its Application for Functional Analysis of Thioredoxin Peroxidase-1. *PLoS one* **10**, e0125993, https://doi.org/10.1371/journal.pone.0125993 (2015).
5. Florin-Christensen, M., Suarez, C. E., Rodriguez, A. E., Flores, D. A. & Schnittger, L. Vaccines against bovine babesiosis: where we are now and possible roads ahead. *Parasitology*, 1–30, https://doi.org/10.1017/S0031182014000961 (2014).
6. Oldiges, D. P. et al. Transfected *Babesia bovis* Expressing a Tick GST as a Live Vector Vaccine. *PLoS neglected tropical diseases* **10**, e005152, https://doi.org/10.1371/journal.pntd.005152 (2016).
7. Suarez, C. E., Johnson, W. C., Herndon, D. R., Laughery, J. M. & Davis, W. C. Integration of a transfected gene into the genome of *Babesia bovis* occurs by legitimate homologous recombination mechanisms. *Molecular and biochemical parasitology* **202**, 23–28, https://doi.org/10.1016/j.molbiopara.2015.09.003 (2015).
8. Suarez, C. E., Laughery, J. M., Schneider, D. A., Sondgeroth, K. S. & McElwain, T. F. Acute and persistent infection by a transfected Mo7 strain of *Babesia bovis*. *Molecular and biochemical parasitology* **185**, 52–57, https://doi.org/10.1016/j.molbiopara.2012.05.003 (2012).
9. Suarez, C. E., Bishop, R. P., Alzan, H. F., Poole, W. A. & Cooke, B. M. Advances in the application of genetic manipulation methods to apicomplexan parasites. *International journal for parasitology* **47**, 701–710, https://doi.org/10.1016/j.ijpara.2017.06.002 (2017).
10. Silva, M. G., Knowles, D. P. & Suarez, C. E. Identification of interchangeable cross-species function of elongation factor-1 alpha promoters in *Babesia bigemina* and *Babesia bovis*. *Parasites & vectors* **9**, 376, https://doi.org/10.1186/s13071-016-1859-9 (2016).
11. Vega, C. A., Buening, G. M., Green, T. J. & Carson, C. A. *In vitro* cultivation of *Babesia bigemina*. *American journal of veterinary research* **46**, 416–420 (1985).
12. Levy, M. G. & Ristic, M. *Babesia bovis*: continuous cultivation in a microaerophilic stationary phase culture. *Science* **207**, 1218–1220 (1980).
13. Alzan, H. E. et al. Geno- and phenotypic characteristics of a transfected *Babesia bovis* 6-Cys-E knockout clonal line. *Parasites & vectors* **10**, 214, https://doi.org/10.1186/s13071-017-2143-3 (2017).
14. Vidotto, O. et al. *Babesia bigemina*: identification of B cell epitopes associated with parasitized erythrocytes. *Experimental parasitology* **81**, 491–500, https://doi.org/10.1006/expr.1995.1142 (1995).
15. de Waal, D. T. & Combrink, M. P. Live vaccines against bovine babesiosis. *Veterinary parasitology* **138**, 88–96, https://doi.org/10.1016/j.vetpar.2006.01.042 (2006).
16. Silva, M. G. et al. First survey for *Babesia bovis* and *Babesia bigemina* infection in cattle from Central and Southern regions of Portugal using serological and DNA detection methods. *Veterinary parasitology* **166**, 66–72, https://doi.org/10.1016/j.vetpar.2009.07.031 (2009).
17. Silva, M. G., Marques, P. X. & Oliva, A. Detection of *Babesia* and *Theileria* species infection in cattle from Portugal using a reverse line blotting method. *Veterinary parasitology* **174**, 199–205, https://doi.org/10.1016/j.vetpar.2010.08.038 (2010).

Acknowledgements
This work was supported by United States Department of Agriculture-Agriculture Research Service Current Research Information System Project No. 5348-32000-028-00D. The funders had no role in study design, data analysis, or preparation and decision to publish the manuscript. We are thankful to Paul Lacy for outstanding technical help in the development of the stable transfection system and for the *B. bovis* and *B. bigemina* cultures, and to Annette Hebert for her help with the immunoblot assay.

Author Contributions
M.G.S. and C.E.S. designed the study, collaborated in performing the stable transfection system and analyzed the results of experiments. M.G.S., D.P.K., M.L.M., B.M.C. and C.E.S. discussed the dataset and wrote the manuscript. All authors read, edited and approved the final version of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23010-4.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.